Cargando…
A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants
BACKGROUND: The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. In contrast to earlier NNRTIs, rilpivirine retains potency against well-character...
Autores principales: | Johnson, Barry C, Pauly, Gary T, Rai, Ganesha, Patel, Disha, Bauman, Joseph D, Baker, Heather L, Das, Kalyan, Schneider, Joel P, Maloney, David J, Arnold, Eddy, Thomas, Craig J, Hughes, Stephen H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549755/ https://www.ncbi.nlm.nih.gov/pubmed/23217210 http://dx.doi.org/10.1186/1742-4690-9-99 |
Ejemplares similares
-
Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants
por: Smith, Steven J., et al.
Publicado: (2016) -
Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase
por: Kuroda, Daniel G., et al.
Publicado: (2013) -
HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism
por: Das, Kalyan, et al.
Publicado: (2012) -
Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE
por: Crauwels, HM, et al.
Publicado: (2010) -
Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine
por: Singh, Abhimanyu K., et al.
Publicado: (2022)